Deepa Manwani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9605825/publications.pdf

Version: 2024-02-01

95	1,797	471061	288905
papers	citations	17 h-index	40 g-index

102	102	102	2759
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Transition Navigator Intervention Improves Transition Readiness to Adult Care for Youth With Sickle Cell Disease. Academic Pediatrics, 2022, 22, 422-430.	1.0	6
2	OUP accepted manuscript. Pain Medicine, 2022, , .	0.9	0
3	GRNDaD: big data and sickle cell disease. Blood Advances, 2022, 6, 1088-1088.	2.5	4
4	Demandâ€only patientâ€controlled analgesia for treatment of acute vasoâ€occlusive pain in sickle cell disease. Pediatric Blood and Cancer, 2022, 69, e29665.	0.8	2
5	50 Years Ago in T J P. Journal of Pediatrics, 2022, 243, 68.	0.9	2
6	Using the â€œCoach Approachâ€• A Novel Peer Mentorship Program for Pediatric Faculty. Academic Pediatrics, 2022, 22, 1257-1259.	1.0	3
7	An Analysis of Racial and Ethnic Backgrounds Within the CASiRe International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research. Journal of Racial and Ethnic Health Disparities, 2021, 8, 99-106.	1.8	11
8	Hemolysis inhibits humoral B-cell responses and modulates alloimmunization risk in patients with sickle cell disease. Blood, 2021, 137, 269-280.	0.6	16
9	Nocturnal hypertension associated with stroke and silent cerebral infarcts in children with sickle cell disease. Pediatric Blood and Cancer, 2021, 68, e28883.	0.8	11
10	Children and young adults hospitalized for severe COVIDâ€19 exhibit thrombotic coagulopathy. Pediatric Blood and Cancer, 2021, 68, e28975.	0.8	37
11	Vasculoâ€toxic and proâ€inflammatory action of unbound haemoglobin, haem and iron in transfusionâ€dependent patients with haemolytic anaemias. British Journal of Haematology, 2021, 193, 637-658.	1.2	22
12	Age of first pain crisis and associated complications in the CASiRe international sickle cell disease cohort. Blood Cells, Molecules, and Diseases, 2021, 88, 102531.	0.6	8
13	P-selectin and sickle cell disease: a balancing act. Blood, 2021, 137, 2573-2574.	0.6	3
14	Type I interferon is induced by hemolysis and drives antibody-mediated erythrophagocytosis in sickle cell disease. Blood, 2021, 138, 1162-1171.	0.6	26
15	Murine bone marrow mesenchymal stromal cells have reduced hematopoietic maintenance ability in sickle cell disease. Blood, 2021, 138, 2570-2582.	0.6	12
16	Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York. Haematologica, 2021, 106, 3014-3016.	1.7	32
17	Gaps in the diagnosis and management of iron overload in sickle cell disease: a â€˜realâ€worldâ€™ report from the GRNDaD registry. British Journal of Haematology, 2021, 195, e157-e160.	1.2	4
18	Paul S. Frenette (1965â€“2021). Cell, 2021, 184, 5073-5076.	13.5	1

#	Article	IF	Citations
19	Global geographic differences in healthcare utilization for sickle cell disease pain crises in the CASiRe cohort. Blood Cells, Molecules, and Diseases, 2021, 92, 102612.	0.6	6
20	Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. Blood Advances, 2021, 5, 207-215.	2.5	59
21	Very low incidence of <i>Clostridioides difficile</i> infection in pediatric sickle cell disease patients. Haematologica, 2021, 106, 1489-1490.	1.7	3
22	Paul S. Frenette (1965â€“2021). Cell Stem Cell, 2021, 28, 1686-1689.	5.2	0
23	Early Evaluation of the Use of Crizanlizumab in Sickle Cell Disease: A National Alliance of Sickle Cell Centers Study. Blood, 2021, 138, 3113-3113.	0.6	4
24	Rare Cases of Infusion-Related Reactions (IRRs) Presenting As Pain Events during or after Crizanlizumab Infusion in Patients (Pts) with Sickle Cell Disease (SCD): A Systematic Evaluation of Post-Marketing (PM) Reports. Blood, 2021, 138, 3112-3112.	0.6	4
25	Pediatric Hydroxyurea Treatment Patterns, Sickle Cell Disease-Related Complication Rates, and Costs in a Large US Administrative Claims Database: A Retrospective Analysis. Blood, 2021, 138, 4055-4055.	0.6	0
26	Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. Therapeutic Advances in Hematology, 2020, 11, 204062072095500.	1.1	22
27	Acute chest syndrome in the setting of SARSâ€COVâ€2 infectionsâ€”A case series at an urban medical center in the Bronx. Pediatric Blood and Cancer, 2020, 67, e28579.	0.8	15
28	Development of a Severity Classification System for Sickle Cell Disease . ClinicoEconomics and Outcomes Research, 2020, Volume 12, 625-633.	0.7	12
29	A study of the geographic distribution and associated risk factors of leg ulcers within an international cohort of sickle cell disease patients: the CASiRe group analysis. Annals of Hematology, 2020, 99, 2073-2079.	0.8	17
30	Pulmonary disease burden in Hispanic and nonâ€Hispanic children with sickle cell disease. Pediatric Pulmonology, 2020, 55, 2064-2073.	1.0	1
31	Randomized phase 2 trial of Intravenous Gamma Globulin (IVIG) for the treatment of acute vaso-occlusive crisis in patients with sickle cell disease: Lessons learned from the midpoint analysis. Complementary Therapies in Medicine, 2020, 52, 102481.	1.3	5
32	Liver Stiffness Measurement by Vibration Controlled Transient Elastography Does Not Correlate to Hepatic Iron Overload in Children With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2020, 42, 214-217.	0.3	3
33	Ambulatory Hypertension in Pediatric Patients With Sickle Cell Disease and Its Association With End-Organ Damage. Cureus, 2020, 12, e11707.	0.2	4
34	Venous Thromboembolism Prophylaxis Practices for Patients with Sickle Cell Disease Pre and during the COVID-19 Pandemic. Blood, 2020, 136, 38-39.	0.6	1
35	Nocturnal Hypertension Associated with Stroke and Silent Cerebral Infarcts in Children with Sickle Cell Disease. Blood, 2020, 136, 10-11.	0.6	0
36	Mental Health Assessment of Youth with Sickle Cell Disease and Their Primary Caretakers: Baseline Depression and COVID-19 Pandemic-Associated Psychosocial Stress in a Multi-Site Study. Blood, 2020, 136, 41-42.	0.6	0

#	Article	IF	Citations
37	Children and Young Adults Admitted to a NYC Children's Hospital Had a Similar Rate of Severe COVID-19 Coagulopathy As That Reported in Older Adults. Blood, 2020, 136, 27-28.	0.6	2
38	The Grndad Registry: Contemporary Natural History Data and an Analysis of Real-World Patterns of Use and Limitations of Disease Modifying Therapy in Adults with SCD. Blood, 2020, 136, 34-36.	0.6	7
39	Splenectomy is not associated with a higher tricuspid regurgitant jet velocity in people with sickle cell anemia. Pediatric Blood and Cancer, 2019, 66, e27928.	0.8	1
40	Airway Inflammation and Lung Function in Sickle Cell Disease. Pediatric, Allergy, Immunology, and Pulmonology, 2019, 32, 92-102.	0.3	9
41	Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD. Blood, 2019, 134, 579-590.	0.6	20
42	A physicians survey assessing management of pulmonary airway involvement in sickle cell disease. Pediatric Pulmonology, 2019, 54, 993-1001.	1.0	5
43	Genetic disarray follows mutant KLF1-E325K expression in a congenital dyserythropoietic anemia patient. Haematologica, 2019, 104, 2372-2380.	1.7	17
44	Altered parasite life-cycle processes characterize Babesia divergens infection in human sickle cell anemia. Haematologica, 2019, 104, 2189-2199.	1.7	7
45	Greater number of perceived barriers to hydroxyurea associated with poorer healthâ€related quality of life in youth with sickle cell disease. Pediatric Blood and Cancer, 2019, 66, e27740.	0.8	11
46	Association Between Periodic Limb Movements in Sleep and Cerebrovascular Changes in Children With Sickle Cell Disease. Journal of Clinical Sleep Medicine, 2019, 15, 1011-1019.	1.4	3
47	HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol. BMC Pediatrics, 2019, 19, 354.	0.7	7
48	Novel findings from the multinational <scp>DOVE</scp> study on geographic and ageâ€related differences in pain perception and analgesic usage in children with sickle cell anaemia. British Journal of Haematology, 2019, 184, 1058-1061.	1.2	13
49	Prenatal Hemoglobinopathy Screening Practices: Areas for Improvement. Blood, 2019, 134, 2298-2298.	0.6	1
50	2'-O-Methoxyethyl Splice-Switching Oligos to Reverse Splicing from IVS2-745 Î²-Thalassemia Patient Cells: A Foundation for Potential Therapies. Blood, 2019, 134, 2244-2244.	0.6	0
51	Long-Term Hydroxyurea Use Is Associated with Lower Levels of Hematopoietic Stem and Progenitor Cells in Patients with Sickle Cell Disease. Blood, 2019, 134, 985-985.	0.6	1
52	Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel. Blood, 2019, 134, 415-415.	0.6	3
53	Chronic Kidney Disease Is Under-Screened in SCD and Mild Albuminuria Is Associated with a Drop in Hemoglobin: A Report from the Grndad Sickle Cell Registry. Blood, 2019, 134, 2284-2284.	0.6	0
54	Common Myeloid Progenitors As Biomarkers of Hbf Response to Hydroxyurea in Sickle Cell Disease. Blood, 2019, 134, 4827-4827.	0.6	0

#	Article	IF	Citations
55	An Analysis of Racial and Ethnic Backgrounds within the Casire International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research. Blood, 2019, 134, 2305-2305.	0.6	0
56	HO-1hi patrolling monocytes protect against vaso-occlusion in sickle cell disease. Blood, 2018, 131, 1600-1610.	0.6	33
57	Airway inflammation in sickle cell diseaseâ€"A translational perspective. Pediatric Pulmonology, 2018, 53, 400-411.	1.0	14
58	Novel Sickle Cell Disease Therapies: Targeting Pathways Downstream of Sickling. Seminars in Hematology, 2018, 55, 68-75.	1.8	12
59	HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease. Journal of Pediatrics, 2018, 197, 177-185.e2.	0.9	13
60	Association of silent infarcts in sickle cell anemia with decreased annexin A5 resistance. Blood Cells, Molecules, and Diseases, 2018, 69, 53-56.	0.6	1
61	New insights into the pathophysiology and development of novel therapies for sickle cell disease. Hematology American Society of Hematology Education Program, 2018, 2018, 493-506.	0.9	23
62	An age dependent response to hydroxyurea in pediatric sickle cell anemia patients with alpha thalassemia trait. Blood Cells, Molecules, and Diseases, 2017, 66, 19-23.	0.6	0
63	Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10â€"18 years through community health workers: The HABIT study. Pediatric Blood and Cancer, 2017, 64, e26689.	0.8	27
64	Intranasal fentanyl for initial treatment of vasoâ€•occlusive crisis in sickle cell disease. Pediatric Blood and Cancer, 2017, 64, e26332.	0.8	30
65	Decreased Hospital Readmissions for Vaso Occlusive Crisis with Implementation of a Sickle Cell Pain Action Plan (SPAP). Blood, 2017, 130, 867-867.	0.6	4
66	Protective Role of HO-1 Expressing CD16+ Patrolling Monocytes Against Hemolysis-Induced Endothelial Damage and Vaso-Occlusive Crisis in Sickle Cell Disease. Blood, 2017, 130, 767-767.	0.6	0
67	Habit, a Feasibility Trial to Improve Hydroxyurea Adherence, Improves Quality of Life in Youth with Sickle Cell Disease. Blood, 2017, 130, 869-869.	0.6	0
68	Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers. Blood, 2016, 128, 1139-1143.	0.6	69
69	Allogeneic bone marrow transplantation for treatment of severe hemolytic anemia attributable to hexokinase deficiency. Blood, 2016, 128, 735-737.	0.6	3
70	Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use. Pediatric Blood and Cancer, 2016, 63, 2146-2153.	0.8	25
71	Intrapatient variability in fetal hemoglobin measurements over time in sickle cell patients not on fetal hemoglobin inducing agents. American Journal of Hematology, 2016, 91, E11-2.	2.0	1
72	Challenging diagnosis and treatment of <scp>HIT</scp> in child with ventricular assistance device. Pediatric Transplantation, 2015, 19, E152-6.	0.5	2

#	Article	IF	Citations
73	A novel inflammatory role for platelets in sickle cell disease. Platelets, 2015, 26, 726-729.	1.1	38
74	Singleâ€dose intravenous gammaglobulin can stabilize neutrophil <scp>M</scp>acâ€1 activation in sickle cell pain crisis. American Journal of Hematology, 2015, 90, 381-385.	2.0	34
75	Neutrophil ageing is regulated by the microbiome. Nature, 2015, 525, 528-532.	13.7	627
76	Altered Heme-Mediated Modulation of Dendritic Cell Function in Sickle Cell Alloimmunization. Blood, 2015, 126, 655-655.	0.6	0
77	Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood, 2014, 123, 3818-3827.	0.6	281
78	Serial assessment of laser Doppler flow during acute pain crises in sickle cell disease. Blood Cells, Molecules, and Diseases, 2014, 53, 277-282.	0.6	9
79	KLF1: when less is more. Blood, 2014, 124, 672-673.	0.6	12
80	Hydroxyurea Response in Pediatric Sickle Cell Disease Patients with Alpha Thalasssemia Trait. Blood, 2014, 124, 1377-1377.	0.6	1
81	Vaso-Occlusion-Promoting Neutrophil Mac-1 Integrin Activation in Human Sickle Cell Crises Is Stabilized By a Single Dose of Intravenous Gammaglobulin. Blood, 2014, 124, 4089-4089.	0.6	4
82	Reducing Health Care Utilization in Sickle Cell Disease Patients By Implementation of an Individualized, Multimodal Care Plan during Hospital Admission and at Inpatient to Outpatient Discharge. Blood, 2014, 124, 444-444.	0.6	5
83	Intra-Patient Variability in Fetal Hemoglobin Measurements over Time in Sickle Cell Disease Patients Not on Fetal Hemoglobin Inducing Agents. Blood, 2014, 124, 4096-4096.	0.6	0
84	Association of Annexin A5 Resistance with Silent Infarct in Sickle Cell Disease. Blood, 2014, 124, 1394-1394.	0.6	0
85	Hydroxyurea Adherence By Personal Best HbF and the 2-Site â€œHABITâ€•Intervention Trial for Pediatric Sickle Cell Disease. Blood, 2014, 124, 1383-1383.	0.6	0
86	Sickle Cell Disease Proteinuria Is Not Associated With Systolic Blood Pressure, CSSCD-Defined Hypertension, or Family History Of Hypertension In An International Cohort Of SCD Patients. Blood, 2013, 122, 981-981.	0.6	11
87	Splenectomy Is Not Associated With Higher Tricuspid Regurgitant Jet Velocity In Patients With Sickle Cell Disease. Blood, 2013, 122, 1002-1002.	0.6	0
88	Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity. Evidence-Based Medicine, 2012, 17, 37-38.	0.6	6
89	A unique presentation of Wiskottâ€“Aldrich syndrome in relation to platelet size. Pediatric Blood and Cancer, 2011, 56, 1127-1129.	0.8	19
90	Case Report of Erythroid Transcription Factor EKLF Mutation Causing a Rare Form of Congenital Dyserythropoetic Anemia in a Patient of Taiwanese Origin. Blood, 2011, 118, 2154-2154.	0.6	5

#	Article	IF	Citations
91	The Human Ankyrin Insulator Supports Production of Therapeutic Levels of Adult Hemoglobin Following Î²-Globin Gene Transfer in Hematopoietic Cells Derived From Thalassemic and Sickle Cell Patients. Blood, 2011, 118, 2055-2055.	0.6	6
92	Effect of Hydroxyurea on Elevated Pulmonary Artery Pressures in Children with Sickle Cell Disease. Blood, 2011, 118, 4841-4841.	0.6	15
93	Stem Cell Transplantation for Children with Sickle Cell Anemia: Factors Associated with Parent and Patient Interest. Blood, 2011, 118, 1079-1079.	0.6	0
94	Throwing out the baby. Blood, 2010, 116, 154-155.	0.6	1
95	Mental health assessment of youth with sickle cell disease and their primary caregivers during the COVIDâ€19 pandemic. Pediatric Blood and Cancer, 0, , .	0.8	1